Want to see HK:1177 full AI Analyst Report?
Top Page
Sino Biopharmaceutical
(1177)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$5.50
▼(-2.48% Downside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by a solid financial base (strong gross profitability and improved free cash flow), but is tempered by weaker net profitability and higher leverage versus last year. Technicals are mixed with improving short-term trend but still below the 200-day average, and valuation is a key headwind due to the high P/E and modest dividend yield.
Positive Factors
Reaccelerating Revenue Growth
Improving top-line growth indicates stronger product demand and commercialization momentum. Sustained expansion across the company’s branded generic and innovative medicine portfolio could support scale, market reach, and future operating leverage.
Negative Factors
Declining Net Profitability
The sharp decline in net margin reduces confidence that strong gross economics consistently translate into bottom-line earnings. If sustained, weaker profitability could constrain internal investment capacity and make future results more sensitive to operating and financing costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Reaccelerating Revenue Growth
Improving top-line growth indicates stronger product demand and commercialization momentum. Sustained expansion across the company’s branded generic and innovative medicine portfolio could support scale, market reach, and future operating leverage.
Read all positive factors
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$104.08B
Dividend Yield2.14%
Average Volume (3M)87.41M
Price to Earnings (P/E)36.1
Beta (1Y)0.97
Revenue Growth14.57%
EPS Growth-31.09%
CountryHK
Employees22,838
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.13
Shares Outstanding18,682,953,000
10 Day Avg. Volume90,071,802
30 Day Avg. Volume87,413,268
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.73Price Target Upside54.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.25
Revenue Forecast (FY)HK$36.29B
Sino Biopharmaceutical Business Overview & Revenue Model
Company Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medi...
How the Company Makes Money
Sino Biopharmaceutical primarily makes money by selling pharmaceutical products it develops or licenses, with revenue recognized from the commercial sale and distribution of medicines. Its key revenue stream is product sales from its drug portfoli...
Sino Biopharmaceutical Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
64
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.70B | 31.83B | 28.87B | 26.20B | 26.03B | 26.86B |
| Gross Profit | 27.78B | 26.13B | 23.53B | 21.21B | 21.54B | 21.53B |
| EBITDA | 10.41B | 7.26B | 6.11B | 6.98B | 6.69B | 19.87B |
| Net Income | 2.39B | 2.34B | 3.50B | 2.33B | 2.54B | 14.61B |
Balance Sheet | ||||||
| Total Assets | 83.21B | 76.04B | 65.41B | 63.60B | 64.06B | 60.54B |
| Cash, Cash Equivalents and Short-Term Investments | 27.58B | 22.96B | 14.60B | 14.12B | 16.92B | 15.79B |
| Total Debt | 17.17B | 16.08B | 9.78B | 12.58B | 13.98B | 12.12B |
| Total Liabilities | 36.96B | 33.32B | 22.63B | 25.43B | 26.12B | 22.81B |
| Stockholders Equity | 32.57B | 30.68B | 31.96B | 30.47B | 29.75B | 30.29B |
Cash Flow | ||||||
| Free Cash Flow | 5.16B | 7.59B | 5.22B | 4.36B | 4.56B | 3.47B |
| Operating Cash Flow | 6.13B | 9.29B | 6.62B | 6.07B | 6.27B | 5.37B |
| Investing Cash Flow | -5.13B | -12.41B | -1.71B | -756.98M | -4.07B | -2.52B |
| Financing Cash Flow | 2.58B | 4.16B | -6.32B | -6.55B | -3.19B | -3.23B |
Sino Biopharmaceutical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$41.70B | 4.16 | 30.16% | 1.55% | 101.73% | 249.15% | |
64 Neutral | HK$35.93B | 36.15 | 20.41% | ― | 32.63% | 8.87% | |
63 Neutral | HK$104.08B | 36.08 | 7.56% | 2.14% | 14.57% | -31.09% | |
63 Neutral | HK$174.74B | 118.66 | 6.06% | ― | 42.64% | 9.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$88.61B | -78.18 | -10.86% | ― | 42.47% | -15.80% | |
46 Neutral | HK$34.13B | -75.42 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:1177
Sino Biopharmaceutical
5.48
-2.76
-33.47%
HK:1801
Innovent Biologics
94.35
-2.75
-2.83%
HK:1530
3SBio
15.54
-15.95
-50.66%
HK:9926
Akeso, Inc.
93.60
-34.10
-26.70%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.14
-16.44
-48.96%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
64.50
-14.95
-18.82%
Sino Biopharmaceutical Corporate Events
Sino Biopharm Wins Trial Nod for Novel Obesity Antibody TQF6422
Aug 21, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has obtained approval from China’s drug regulator to begin clinical trials of TQF6422, a fully human ActRII A/B monoclonal antibody for weight management in obese and overweight adu...
Sino Biopharmaceutical Interim Results Highlight Surge in Innovative Drug and Out-Licensing Revenue
Aug 19, 2026
Sino Biopharmaceutical reported solid interim results for the six months ended 30 June 2026, with revenue rising 10.6% year-on-year to RMB19.44 billion and profit attributable to shareholders edging up 1.4% to RMB3.43 billion. The company declared...
Sino Biopharmaceutical Declares 2026 Interim Dividend of HKD 0.07 Per Share
Aug 19, 2026
Sino Biopharmaceutical Limited has announced an interim ordinary cash dividend of HKD 0.07 per share for the six months ended 30 June 2026, payable in Hong Kong dollars. The ex-dividend date is set for 1 September 2026, with the record date on 4 S...
Sino Biopharm Wins NMPA Approval for New First-Line Lung Cancer Regimen
Aug 7, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration for a new first-line regimen for locally advanced or metastatic squamous non-small cell lung cancer. The t...
Sino Biopharm Wins Approval for Next-Generation Flurbiprofen Pain Patch
Aug 6, 2026
Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has secured approval from China’s National Medical Products Administration to market a second-generation flurbiprofen patch for a broad range of pain and inflammatory indi...
Sino Biopharmaceutical Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 6, 2026
Sino Biopharmaceutical Limited has scheduled a board meeting for 19 August 2026 to approve the publication of its unaudited interim results for the six months ended 30 June 2026 and to consider the declaration of an interim dividend. The outcome o...
Sino Biopharm Wins China CDE Acceptance for Novel Leukemia Drug TQB3909
Aug 4, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has had its new drug application for TQB3909, a Category 1 innovative BCL-2 inhibitor tablet, accepted by China’s Center for Drug Evaluation for use in adult patients with relapsed ...
Sino Biopharm’s HER2 bispecific ADC TQB2102 gains third breakthrough tag in China
Aug 3, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured a third Breakthrough Therapy Designation in China for its next-generation HER2 bispecific antibody-drug conjugate TQB2102, this time for adult patients with unresectable or me...
Sino Biopharmaceutical to Showcase 21 Oncology Studies at 2026 CSCO Meeting
Jul 30, 2026
Sino Biopharmaceutical announced it will present 21 new oncology research results at the 2026 Chinese Society of Clinical Oncology Annual Meeting, including five oral presentations. The data spans a pipeline IDH1 inhibitor TQB3454 and several mark...
Sino Biopharmaceutical Forms Indonesia Joint Venture With Tempo Scan
Jul 27, 2026
Sino Biopharmaceutical has formed a strategic joint venture with Indonesian healthcare group PT Tempo Scan Pacific Tbk to expand access to innovative medicines in Indonesia. The new entity, PT Tempo CTTQ Biopharmaceutical Indonesia, will leverage ...
Sino Biopharm Wins NMPA Nod for Innovative Hepatitis B Drug Trial
Jul 23, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration to begin clinical trials of IM-101, a PreS1 recombinant fusion protein developed as a national Category 1 ...
Sino Biopharmaceutical Wins Breakthrough Status for AI-Designed Neuropathic Pain Drug TRD205
Jul 14, 2026
Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has advanced TRD205, a National Category 1 innovative drug targeting peripheral AT2R receptors, through a Phase II trial for chronic post-surgical neuropathic pain, leading to B...
Sino Biopharm’s IDH1 Inhibitor for Biliary Tract Cancer Wins China NDA Acceptance
Jul 10, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has had its new drug application for TQB3454, an IDH1 inhibitor tablet, accepted by China’s Center for Drug Evaluation for treating advanced biliary tract cancer with IDH1 mutations...
Sino Biopharm Deepens GSK Respiratory Deal to Cement China Lead
Jul 8, 2026
Sino Biopharmaceutical is a leading Chinese pharmaceutical group with a strong presence in respiratory, oncology and liver disease therapies. Through subsidiary Chia Tai Tianqing Pharmaceutical, it has built one of China’s largest innovative...
Sino Biopharm Strikes $2.1 Billion Global Respiratory Drug Deal with AstraZeneca
Jul 7, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has signed an exclusive license agreement with AstraZeneca granting the British drugmaker rights to develop, manufacture and commercialize the inhaled PDE3/4 inhibitor TQC3721 outside Chi...
Sino Biopharm’s Long-Acting Ropivacaine Analgesic Wins NDA Acceptance in China
Jul 3, 2026
Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has had its new drug application for a ropivacaine hydrochloride sustained-release solution accepted by China’s Center for Drug Evaluation, targeting postoperative long-ac...
Sino Biopharmaceutical Wins Priority Review for CLDN18.2 Gastric Cancer Drug
Jun 23, 2026
Sino Biopharmaceutical’s subsidiary LaNova Medicines has had its new drug application for tecotabart vedotin, a CLDN18.2-targeting antibody-drug conjugate known as LM-302, accepted by China’s Center for Drug Evaluation for CLDN18.2-pos...
Sino Biopharmaceutical Wins China Approval for First-in-Class Peceleganan Spray
Jun 23, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration for Peceleganan Spray, a national Category 1 innovative drug for treating wound infections from first-degr...
Sino Biopharmaceutical Adds Leading Scientists to Board as Independent Directors
Jun 17, 2026
Sino Biopharmaceutical has appointed renowned scientists Dr. Chen Lieping and Dr. Lu Bai as independent non-executive directors, effective after its annual general meeting on 17 June 2026. The move brings high-profile expertise in cancer immunothe...
Sino Biopharmaceutical Details Board Composition and Governance Committee Roles
Jun 17, 2026
Sino Biopharmaceutical has confirmed the current composition of its board, listing five executive directors, including chairwoman Theresa Tse and CEO Eric Tse, alongside six independent non‑executive directors. The disclosure reinforces the ...
Sino Biopharmaceutical Wins Strong Shareholder Backing at 2026 AGM
Jun 17, 2026
Sino Biopharmaceutical shareholders approved all resolutions at the 17 June 2026 annual general meeting, including adoption of the 2025 audited financial statements and the payment of a final dividend. Investors also backed the re-election of dire...
Sino Biopharm’s ST2 Antibody Shows Promising Phase II Results in Allergic Rhinitis
Jun 15, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing reported Phase II data for TQC2938, a humanised ST2 monoclonal antibody, in adults with moderate-to-severe seasonal allergic rhinitis who had inadequate response to standard intranasal co...
Sino Biopharmaceutical Unveils HK$2 Billion Share Purchase Plan to Support Stock and Shareholders
Jun 14, 2026
Sino Biopharmaceutical’s board has launched a share purchase plan in response to recent share price volatility, arguing that the company’s value is being significantly underestimated by the market. The plan allows for up to HK$2 billio...
Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer
Jun 1, 2026
Sino Biopharmaceutical reported Phase II data for its oral CDK2/4/6 inhibitor culmerciclib, combined with fulvestrant, in hormone receptor-positive, HER2-negative advanced breast cancer patients who had progressed on prior CDK4/6 inhibitor and end...
Sino Biopharm’s LM-302 Gastric Cancer Data Pave Way for Chemo‑Free Phase III Trial
May 31, 2026
Sino Biopharmaceutical announced Phase II clinical results for tecotabart vedotin (LM-302), a CLDN18.2-targeting antibody-drug conjugate developed by subsidiary LaNova Medicines, in first-line treatment of CLDN18.2-positive advanced gastric or gas...
Sino Biopharm Showcases Promising Phase I Data for Novel EGFR/c-Met ADC at ASCO 2026
May 31, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported Phase I data for TQB6411, an EGFR/c-Met antibody-drug conjugate, in patients with advanced solid tumors who had failed standard therapies. The drug, one of the first EGFR/c-M...
Sino Biopharm Reports Landmark Phase III Win for Benmelstobart Combo in Lung Cancer
May 31, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported Phase III data showing that its anti-PD-L1 antibody benmelstobart combined with platinum chemotherapy, followed by benmelstobart plus anlotinib, significantly extended progre...
Sino Biopharm Wins China-Wide Approval for Opioid-Induced Constipation Drug
May 29, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured National Medical Products Administration approval to market Naldemedine Tosylate Tablets in China for opioid-induced constipation in adults, extending earlier regional clearan...
Sino Biopharm, GSK Report Pivotal Phase III Success for Hepatitis B Drug Bepirovirsen
May 28, 2026
Sino Biopharmaceutical said its subsidiary Chia Tai Tianqing and partner GSK have reported positive pivotal data from two Phase III trials of bepirovirsen for chronic hepatitis B. The results, unveiled at the EASL 2026 Congress and published in th...
Sino Biopharm’s IDH1 Inhibitor for Biliary Tract Cancer Wins Priority Review in China
May 28, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has advanced its innovative IDH1 inhibitor TQB3454, designed to treat patients with locally advanced, recurrent, or metastatic biliary tract cancer harboring IDH1 mutations who have faile...
Sino Biopharm’s Liver-Targeted THR Agonist Kylo-0603 Shows Favorable Phase I Data
May 27, 2026
Sino Biopharmaceutical announced Phase I clinical data for Kylo-0603, an orally administered GalNAc-conjugated thyroid hormone receptor-beta small molecule agonist developed by its subsidiary Hygieia, presented at the 2026 European Association for...
Sino Biopharm’s Bispecific Antibody M701 Shows Promise in Malignant Effusion Trials
May 22, 2026
Sino Biopharmaceutical said subsidiary Chia Tai Tianqing will present data at the 2026 ASCO meeting from two clinical studies of M701, a CD3/EpCAM bispecific antibody targeting malignant effusions caused by advanced epithelial tumors and non-small...
Sino Biopharmaceutical Wins China First-Line Approval for Oral HER2 Lung Cancer Drug
May 21, 2026
Sino Biopharmaceutical announced that zongertinib, an oral HER2 tyrosine kinase inhibitor it co-promotes with Boehringer Ingelheim, has received conditional approval from China’s National Medical Products Administration as a first-line monot...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.